Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

About this update from Zentalis Pharmaceuticals, Inc.

SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced two presentations at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain. "We are pleased that the overall survival results from the DENALI Part 1b study are accepted as a rapid oral presentation at ESMO." said Julie Eastland, Chief Executive Officer. "The data will showcase the long-term survival benefits demonstrated by azenosertib in patients with Cyclin E1-positive platinum-resistant ovarian cancer in this study and further support our strategic focus on advancing azenosertib in registration-intended monotherapy trials for this biomarker-selected patient population with high unmet need." Rapid oral presentation: Title: "Azenosertib in platinum-resistant ovarian cancer (PROC): overall survival analysis from Part 1b of the DENALI study (GOG-3066)" Date/Time: Friday, October 23, 2026, 4:15 p.m. - 5:45 p.m. CEST Presentation Number: 1242RO Trial-in-progress poster presentation: Title: "ASPENOVA: A phase 3 study of azenosertib monotherapy versus standard of care chemotherapy in cyclin E1-positive platinum-resistant ovarian cancer (PROC)" Date/Time: Monday, October 26, 2026, 12:00 p.m. - 12:45 p.m. CEST Presentation Number: 1339TiP About DENALI Clinical Trial   DENALI is a multi-part Phase 2 registration-intended clinical trial (NCT05128825) studying azenosertib in PROC patients. Part 1b enrolled patients with PROC regardless of Cyclin E1 protein expression, all treated at 400mg QD 5:2 (5 days once-daily administration of azenosertib, followed by 2 days without azenosertib). Part 2 is prospectively enrolling PROC patients with Cyclin E1 protein overexpression based on Zentalis' proprietary immunohistochemistry cutoff. Part 2, in total, is designed to support accelerated approval, pending positive study outcomes and further discussions with the FDA. The study design consists of the following parts:

View stock analysis, news, and events for Zentalis Pharmaceuticals, Inc.